IciCLLe trial

Chief investigator - Professor Peter Hillmen, St James's University Hospital
A phase II assessment of the mechanism of action of ibrutinib (PCI-32765) in B-cell receptor pathway inhibition in CLL
Award start date: 01 May 2014
Recruitment start date: 12 Jun 2014
Award duration: 5 years (funding includes the IciCLLe extension study)

At the moment bone marrow transplantation is the only cure for CLL, but some people may not be able to undergo this treatment because they are too frail. Chemotherapy can be effective, but can have serious side effects especially in older people.

Research has shown that ibrutinib (also known as PCI-32765) can help people with CLL. Ibrutinib is a type of biological therapy called a Bruton’s Tyrosine Kinase (BTK) inhibitor that stops signals that cancer cells use to divide and grow. But researchers still need to know more about how it works, so doctors can understand how to combine ibrutinib with other drugs to make more effective treatments.

The main aims of this study were to:

  • Find out more about how ibrutinib works
  • See how well ibrutinib works for people with CLL who haven’t had treatment yet
  • Assess how well ibrutinib works for people whose CLL has continued to get worse during treatment, or came back after treatment

This trial is closed for recruitment, and we hope to update you with the results soon.